ViiVHealthcare US

You are about to leave ViiVMedinfo.
 

By clicking "Allow," you will be taken to a website that is independent of ViiV Healthcare. The site you linking to is not controlled or endorsed by ViiV Healthcare, and ViiV Healthcare is not responsible for the content provided on that site.

This site is intended for US healthcare professionals only.

  • HIV Prevention
  • HIV Treatment
  • Pediatric HIV
  • Report an Adverse Event
ViiVHealthcare
  • Home
  • Congress Presentations
  • HIV Resources
    • HIV Prevention
    • HIV Treatment
    • Pediatric HIV
    • Videos and Events
    • Medical Resources
  • Our HIV Medicines
  • Our Pipeline
  • Connect With Us
    • Our HIV Experts
    • Connect With Us
ViiVHealthcare
  • Home
  • Congress Presentations
  • HIV Resources
    • HIV Prevention
    • HIV Treatment
    • Pediatric HIV
    • Videos and Events
    • Medical Resources
  • Our HIV Medicines
  • Our Pipeline
  • Connect With Us
    • Our HIV Experts
    • Connect With Us
Our HIV Medicines
Show Medicines
Hide Medicines
OUR HIV MEDICINES
  • Apretude
  • Cabenuva
  • Dovato
  • Tivicay / Tivicay PD
  • Juluca
  • Rukobia
  • Triumeq / Triumeq PD
  • Vocabria
  • Combivir
  • Epivir
  • Epzicom
  • Retrovir
  • Selzentry
  • Lexiva
  • Trizivir
  • Viracept
  • Ziagen

Cabenuva

(cabotegravir and rilpivirine)

Cabenuva is a 2-drug co-packaged product of cabotegravir, a HIV-1 integrase strand transfer inhibitor (INSTI), and rilpivirine, an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI).

CABENUVA Implementation Guidance for Clinics Cabenuva Dosing Regimens – Monthly and Q2M Dosing Approved for Use

Prescribing Information

Patient Information

Talk to a Medical Expert

  • Medical Information Documents

    • Data in Virologically Suppressed Patients

      Monthly Administration

      ATLAS, FLAIR, and CUSTOMIZE: Efficacy and Safety Data (MI letter)

      ATLAS and FLAIR: Efficacy and Safety Data (Infographic)

      Data with and without Oral Lead-In

      ATLAS Week 48 Results (CROI 2019)

      FLAIR Week 48 Results (CROI 2019)

      ATLAS and FLAIR Week 48 Pooled Analysis (IAS 2019)

      FLAIR Week 96 Results (CROI 2020)

      ATLAS Week 96 Results (Glasgow 2020)

      Every 2 Month Administration (ATLAS-2M)

      ATLAS-2M (MI letter)

      ATLAS-2M (Infographic)

      Plasma Concentrations through Week 48

      Week 48 Results (CROI 2020)

      Week 96 Results (CROI 2021, Slides)

      Week 152 Results (CROI 2022)

    • Treatment-Emergent Resistance Data

      Overview on Occurrence of Treatment-Emergent Resistance

      In vitro activity

      Patient and Viral Factors on Virologic Outcome

      Analysis across ATLAS, FLAIR, and ATLAS-2M (Glasgow 2020)

    • Data in Viremic Patients

      Use in Viremic Treatment-Experienced Patients

    • Dosage, Administration, and Delivery

      Management of Missed Injections (Monthly, MI letter)

      Management of Missed Injections (Monthly, Infographic)

      Management of Missed Injections (Every 2 Months, MI Letter)

      Management of Missed Injections (Every 2 Months, Infographic)

      Management of Underdosing (Monthly)

      Management of Underdosing (Every 2 Months)

      Change in Dosing Frequency

      Availability of 2-inch Needles

      Impact of COVID-19 on Dosing Visits (IDWeek 2020)

      Use in Patients with Buttock Implants or Dermal Fillers

    • Implementation into Clinical Practice

      CUSTOMIZE - Patient Perspectives

      Considerations for Implementing (MI Letter)

      Considerations for Implementing (Infographic)

    • Status in DHHS and IAS Guidelines

      Status in DHHS and IAS Guidelines

    • Safety Data

      Occurrence of Injection Site Reactions (MI letter)

      Occurrence of Injection Site Reactions (Infographic)

      Post-Injection Reactions

      Effects on Bone

      Effects on Weight (MI Letter)

    • Drug Interactions

      Use with COVID-19 Vaccines and Therapeutics

      Use with Tecovirimat

    • Data in Pediatrics

      Use in Pediatric Patients

    • Special Populations

      Use in Pregnancy

      Use in Patients with Renal or Hepatic Impairment

    • Patient Reported Outcomes

      Monthly Administration (MI letter)

      Monthly Administration (Infographic)

      Every 2 Month Administration

    • Storage and Stability

      Storage Conditions

  • On Demand Medical Videos

    • Congress Data

      Discussing CABENUVA Data at AIDS 2022

      Discussing CABENUVA Data at AIDS 2022

      Bruce Gilliam, MD, FACP Sr. Medical Director, North American Medical Affairs
      Dr. Moti Ramgopal, MD, FIDSA, FACP Associate Professor of Medicine Medical Director Midway Reasearch Center and Found of Midway Specialty Care Centers

      Discussing CABENUVA Data at AIDS 2022

      Bruce Gilliam, MD, FACP Sr. Medical Director, North American Medical Affairs
      Dr. Moti Ramgopal, MD, FIDSA, FACP Associate Professor of Medicine Medical Director Midway Reasearch Center and Found of Midway Specialty Care Centers
      Cabenuva%20Post%20CROI%202022%20Discussion

      Cabenuva Post CROI 2022 Discussion

      Andrew Zolopa, MD—Head North American Medical Affairs, ViiV Healthcare
      Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir, ViiV Healthcare
      Mark Lewandowski, PharmD —Medical Director, ViiV Healthcare

      Cabenuva Post CROI 2022 Discussion

      Andrew Zolopa, MD—Head North American Medical Affairs, ViiV Healthcare
      Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir, ViiV Healthcare
      Mark Lewandowski, PharmD —Medical Director, ViiV Healthcare
      ATLAS 2M Week 152 Data - Discussion and Application to Clinical Practice

      ATLAS 2M Week 152 Data - Discussion and Application to Clinical Practice

      Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir
      Jean Van Wyk, MBChB; MFPM—VP and Global Medical Lead, Cabotegravir

      ATLAS 2M Week 152 Data - Discussion and Application to Clinical Practice

      Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir
      Jean Van Wyk, MBChB; MFPM—VP and Global Medical Lead, Cabotegravir
      Post-CROI 2021 Webinar

      Post-CROI 2021 Webinar

      Andrew Zolopa, MD, VP, Head, North America Medical Affairs

      Post-CROI 2021 Webinar

      Andrew Zolopa, MD, VP, Head, North America Medical Affairs
    • Clinical Trials Data

      Cabenuva%20Post%20CROI%202022%20Discussion

      Cabenuva Post CROI 2022 Discussion

      Andrew Zolopa, MD—Head North American Medical Affairs, ViiV Healthcare
      Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir, ViiV Healthcare
      Mark Lewandowski, PharmD —Medical Director, ViiV Healthcare

      Cabenuva Post CROI 2022 Discussion

      Andrew Zolopa, MD—Head North American Medical Affairs, ViiV Healthcare
      Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir, ViiV Healthcare
      Mark Lewandowski, PharmD —Medical Director, ViiV Healthcare
      ATLAS 2M Week 152 Data - Discussion and Application to Clinical Practice

      ATLAS 2M Week 152 Data - Discussion and Application to Clinical Practice

      Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir
      Jean Van Wyk, MBChB; MFPM—VP and Global Medical Lead, Cabotegravir

      ATLAS 2M Week 152 Data - Discussion and Application to Clinical Practice

      Paula Teichner, PharmD—Regional Medical Lead, Cabotegravir
      Jean Van Wyk, MBChB; MFPM—VP and Global Medical Lead, Cabotegravir
      The ABCs of CAB: Incorporating Long-Acting Cabenuva into Clinical Practice

      The ABCs of CAB: Incorporating Long-Acting Cabenuva into Clinical Practice

      Paula Teichner, PharmD, AAHIVP, Regional Medical Lead

      The ABCs of CAB: Incorporating Long-Acting Cabenuva into Clinical Practice

      Paula Teichner, PharmD, AAHIVP, Regional Medical Lead
      Post-CROI 2021 Webinar

      Post-CROI 2021 Webinar

      Andrew Zolopa, MD, VP, Head, North America Medical Affairs

      Post-CROI 2021 Webinar

      Andrew Zolopa, MD, VP, Head, North America Medical Affairs
    • Data in Virologically Suppressed Patients

      Every 2 Month Administration (ATLAS-2M)
      Week 96 Results (CROI 2021, Video)

      Week 96 Results (CROI 2021, Video)

      Week 96 Results (CROI 2021, Video)

      Week 152 Results – Discussion and Application to Clinical Practice (Video)

      Week 152 Results – Discussion and Application to Clinical Practice (Video)

      Week 152 Results – Discussion and Application to Clinical Practice (Video)

    • Safety Data

      Weight and Lipid Changes (CROI 2021)

      Weight and Lipid Changes (CROI 2021)

      Weight and Lipid Changes (CROI 2021)

  • Implementation Resources

    ViiV resources on considerations to implement Cabenuva into clinical practice:

    CABENUVA Implementation Guidance for Clinics

    Considerations to Implement CABENUVA

    The ABCs of CAB: Incorporating Long-Acting CABENUVA Into Clinical Practice

    For information on select publicly available resources to help providers implement CABENUVA into clinical practice, visit the following:

    AAHIVM Long-Acting Agents Resource Center (hivlaa.org)

    HIVMA: Cabenuva Considerations for Health Care Providers
    long-acting-antiretroviral-treatment-considerations-for-health-care-providers.pdf (hivma.org)

    NYSDOH AIDS Institute Guideline: Use of Injectable CAB/RPV LA as Replacement ART in Virally Suppressed Adults
    Use of Injectable CAB/RPV LA as Replacement ART in Virally Suppressed Adults - AIDS Institute Clinical Guidelines (hivguidelines.org)

  • Talk to Medical Expert
  • Request a Scientific Discussion
  • Chat

Connect With Us

ViiVHealthcare US

Are you a US healthcare provider?
 

This web portal is intended as an educational resource for healthcare providers practicing in the United States. It may include information about products or uses that have not been approved by the US Food and Drug Administration.
 

If you are not a healthcare provider, please discuss any questions you have regarding your health or medicines with your doctor, pharmacist, or nurse.
 

Yes

No

Connect With Our Medical Experts

Find My ViiV MSL

Easily find the ViiV Medical Science Liaison (MSL) in your area.

Talk to a Medical Expert

Connect now with a live ViiV Medical Expert.

Request a Scientific Discussion

Submit a request for additional information from a ViiV Medical Expert.

Contact Us

Chat Live

Get immediate assistance from a ViiV Healthcare Professional.

Call 1‑888‑226‑8434

Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)

Our Response to COVID-19

Report an Adverse Event

To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1‑877‑844‑8872 or FDA at 1‑800‑332‑1088 or www.fda.gov/medwatch

ViiVHealthcare US

This site is intended for US Healthcare Professionals Only. It may include information about products or uses that have not been approved by the US Food and Drug Administration.

 

Trademarks are owned by or licensed to the ViiV Healthcare group of companies.

 

©2022 ViiV Healthcare group of companies or its licensor. Produced in USA. January 2022

  • Terms of Use
  • Cookie Policy
  • Privacy Notice
  • Terms and Conditions
  • ViiVHealthcare.com